Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Revenue (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Revenue for 9 consecutive years, with $7.4 million as the latest value for Q4 2025.

  • Quarterly Revenue fell 95.49% to $7.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $46.0 million through Dec 2025, down 89.27% year-over-year, with the annual reading at $46.0 million for FY2025, 89.41% down from the prior year.
  • Revenue hit $7.4 million in Q4 2025 for Protagonist Therapeutics, up from $4.7 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $255.0 million in Q1 2024 to a low of $900000.0 in Q2 2022.
  • Historically, Revenue has averaged $40.7 million across 5 years, with a median of $8.0 million in 2021.
  • Biggest five-year swings in Revenue: soared 2646.91% in 2021 and later crashed 95.49% in 2025.
  • Year by year, Revenue stood at $8.6 million in 2021, then skyrocketed by 1205.56% to $112.5 million in 2022, then tumbled by 91.11% to $10.0 million in 2023, then surged by 1550.0% to $165.0 million in 2024, then plummeted by 95.49% to $7.4 million in 2025.
  • Business Quant data shows Revenue for PTGX at $7.4 million in Q4 2025, $4.7 million in Q3 2025, and $5.5 million in Q2 2025.